IGF-1 is the hormone that actually carries out most of what growth hormone is credited with — GH largely works by telling the liver to produce it. Supplying IGF-1 directly bypasses that step. The theory is sound; the human evidence for performance use is considerably thinner than the marketing implies.
Its relationship to HGH
Growth hormone circulates and signals the liver to produce IGF-1, which is the mediator of most downstream growth effects. So blood IGF-1 is the standard marker for whether GH is doing anything — a GH protocol that has not raised IGF-1 is not working.
Supplying IGF-1 directly skips the pituitary and liver entirely. That sounds efficient, and it removes a regulatory step the body uses to control the process — the same trade-off as T3 against T4.
Why LR3 exists
Most IGF-1 in your blood is bound to binding proteins and inactive; the free fraction acts. Native IGF-1 also has a very short half-life — minutes.
IGF-1 LR3 is a modified version with two changes that reduce binding-protein affinity and extend half-life substantially. That is the point of it: native IGF-1 clears too fast to be practical.
The corollary is that LR3 is not the hormone your body makes. It is a longer-acting analogue with a different distribution, and human data on it is limited — most of what is cited comes from cell culture and animal work.
What is claimed versus what is shown
- Muscle hyperplasia — the striking claim, that IGF-1 creates new muscle fibres rather than enlarging existing ones. Demonstrated in animal models; not established in adult humans at doses people use.
- Localised growth — the idea that injecting near a muscle grows that muscle specifically. Some local effect is plausible given the short half-life; the dramatic version circulating in gyms is not supported.
- Recovery and repair — the best-supported area, and consistent with IGF-1’s role in tissue repair generally.
- Fat loss — weakly supported. Some effects are attributable to associated insulin sensitivity changes rather than fat loss as such.
The risks worth taking seriously
- Hypoglycaemia. IGF-1 has meaningful insulin-like activity — it lowers blood glucose. This is the acute risk, and it is the same mechanism described in the insulin article. It is not usually as severe, but it is the same category of problem and deserves the same respect.
- Growth is indiscriminate. IGF-1 promotes proliferation in tissue generally. The theoretical concern about existing cancers is the reason it is used cautiously in medicine, and it is not a reason to dismiss lightly.
- Organ growth at sustained high doses, as with GH.
On cost and authenticity
IGF-1 is expensive to produce and short-lived in solution, which makes it a poor candidate for casual handling and an attractive one for substitution. Our IGF-1 category carries 26 lines with prices reflecting genuine production cost.
A cheap IGF-1 listing deserves the same scepticism as cheap growth hormone — see how to check a brand is genuine. It also requires cold handling from arrival, not just after reconstitution.
Frequently asked questions
Is IGF-1 better than HGH?
It is downstream of HGH rather than better. It bypasses the pituitary and liver, which removes a regulatory step — an efficiency and a loss of control at the same time.
Does IGF-1 build muscle in a specific area?
Some local effect is plausible given the short half-life, but the dramatic site-specific growth claimed in gyms is not supported by human evidence.
Can IGF-1 cause hypoglycaemia?
Yes — it has insulin-like activity and lowers blood glucose. Treat it with the same caution regarding food timing and monitoring.